Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 34.80% is 380% above its 5-year average of -12.45%, near the high end of its 5-year range (-65.16%–40.22%).
As of the fiscal period ended Wednesday, December 31, 2025. 24.89% above its 12-month average of 27.86%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
34.80%
RETURN ON EQUITY (ROE) AVG TTM
27.86%
RETURN ON EQUITY (ROE) AVG 3Y
4.54%
RETURN ON EQUITY (ROE) AVG 5Y
-12.45%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.89%
CURRENT VS 3Y AVG
+666.94%
CURRENT VS 5Y AVG
+379.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+219.56%
vs the sector median at left
TransMedics Group, Inc.
Market Cap
$2.80B
Return on Equity (ROE)
34.80%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$2.85B
Return on Equity (ROE)
-47.65%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.19B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$472.11M
Return on Equity (ROE)
-33.14%
TTM Avg
-52.50%
3Y Avg
-47.15%
5Y Avg
-47.15%
Market Cap
$442.89M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$15.31M
Return on Equity (ROE)
-721.75%
TTM Avg
348.35%
3Y Avg
157.32%
5Y Avg
61.09%
Market Cap
$7.04B
Return on Equity (ROE)
-2.97%
TTM Avg
25.09%
3Y Avg
5.57%
5Y Avg
0.40%
Market Cap
$7.88B
Return on Equity (ROE)
-2.37%
TTM Avg
-21.41%
3Y Avg
-36.14%
5Y Avg
-25.75%
Market Cap
$8.24B
Return on Equity (ROE)
-57.18%
TTM Avg
-651.33%
3Y Avg
-315.37%
5Y Avg
-198.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.80B | 34.80% | 27.86% | 4.54% | -12.45% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.85B | -47.65% | -45.75% | -30.11% | -18.95% |
| Teladoc Health, Inc. (TDOC)vs › | $1.19B | -13.54% | -40.81% | -170.75% | -114.78% |
| Shoulder Innovations, Inc. (SI)vs › | $472.11M | -33.14% | -52.50% | -47.15% | -47.15% |
| NRC Health (NRC)vs › | $442.89M | 89.43% | 81.07% | 67.39% | 61.90% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -721.75% | 348.35% | 157.32% | 61.09% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.04B | -2.97% | 25.09% | 5.57% | 0.40% |
| Oscar Health, Inc. (OSCR)vs › | $7.88B | -2.37% | -21.41% | -36.14% | -25.75% |
| Tempus AI, Inc. (TEM)vs › | $8.24B | -57.18% | -651.33% | -315.37% | -198.08% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.04B | 2.46% | -8.94% | -15.72% | 1.14% |
ROE
34.8%
ROA
12.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 40.22% |
| 2024-12-31 | 15.51% |
| 2023-12-31 | -18.24% |
| 2022-12-31 | -19.34% |
| 2021-12-31 | -65.16% |
| 2020-12-31 | -27.67% |
| 2019-12-31 | -61.39% |
| 2018-12-31 | 492.35% |
| 2017-12-31 | 12.34% |
| 2016-12-31 | -62.04% |
